Procarbazine
Title: Procarbazine
CAS Registry Number: 671-16-9
CAS Name: N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
Additional Names: N-isopropyl-a-(2-methylhydrazino)-p-toluamide; N-4-isopropylcarbamoylbenzyl-N¢-methylhydrazine; p-(N1-methylhydrazinomethyl)-N-isopropylbenzamide; ibenzmethyzin; MIH
Manufacturers' Codes: Ro-4-6467
Molecular Formula: C12H19N3O
Molecular Weight: 221.30
Percent Composition: C 65.13%, H 8.65%, N 18.99%, O 7.23%
Literature References: Alkylating agent. Prepn: BE 618638; W. Bollag et al., US 3520926 (1962, 1970 to Hoffmann-La Roche). Toxicity data: E. I. Goldenthal, Toxicol. Appl. Pharmacol. 18, 185 (1971). Comprehensive description: R. J. Rucki, Anal. Profiles Drug Subs. 5, 403-427 (1976). HPLC determn in plasma: X. He et al., J. Chromatogr. B 799, 281 (2004). Review of clinical experience in hematological malignancies: M. Massoud et al., Eur. J. Cancer 40, 1924-1927 (2004).
 
Derivative Type: Hydrochloride
CAS Registry Number: 366-70-1
Trademarks: Matulane (Roche); Natulan (Roche)
Molecular Formula: C12H19N3O.HCl
Molecular Weight: 257.76
Percent Composition: C 55.92%, H 7.82%, N 16.30%, O 6.21%, Cl 13.75%
Properties: Crystals from methanol, mp 223-226°. LD50 orally in rats: 785 ±34 mg/kg (Goldenthal).
Melting point: mp 223-226°
Toxicity data: LD50 orally in rats: 785 ±34 mg/kg (Goldenthal)
 
Derivative Type: Hydrobromide
Molecular Formula: C12H19N3O.HBr
Molecular Weight: 302.21
Percent Composition: C 47.69%, H 6.67%, N 13.90%, O 5.29%, Br 26.44%
Properties: Crystals from methanol + ether, dec 216-217°.
 
CAUTION: Procarbazine hydrochloride is reasonably anticipated to be a human carcinogen: Report on Carcinogens, Eleventh Edition (PB2005-104914, 2004) p III-222.
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Alkylating Agents.

Others monographs:
Bactericidal Permeability-Increasing ProteinKetamineOxatomideHesperidin
DamasceninePosaconazolePirprofenSilver(II) Oxide
PhosphamidonRose BengalTachysterolPerlapine
DiphenoxylateReserpineAlpiroprideNitrohydrochloric Acid
©2016 DrugLead US FDA&EMEA